Our vision is to improve the treatment of severe diseases in order to provide benefits for both patients and society as a whole.
Oasmia launches the ovarian cancer treatment drug Apealea® in Sweden, Denmark and Finland
Watch clip, including interviews with our Chief Medical Officer and Chief Business Officer.
Oasmia and Elevar sign a global strategic partnership for the commercialization of Apealea®
Oasmia has released its Q3 report
We uses cookies in order to optimize your use of our website. Read more about cookies.
